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Abstract
Nickel(II) complexes of thiosemicarbazons were observed to be potent cytotoxic agents in human and
rodent tissue cultured tumor cells. Each compound demonstrated a slightly different profile in the various
histological types ofannors. The nickel complex ofAppip demonstrated the most potent in vivo activity in
the Ehrlich ascites carcinoma. This agent selectively inhibited L1210 DNA and purine syntheses, and
DNA polymerase tx, PRPP-amido transferase, IMP-dehydrogenase, dihydrofolate reductase, TMP-kinase
and thymidylate synthetase activities. L1210 DNA strand scission was evident and DNA viscosity was
reduced after 24 hr incubation. The nickel complexes were not L1210 DNA topoisomerase II inhibitors.
Introduction
Copper, nickel and cobalt metal complexes of heterocyclic thiosemicarbazones, thioureas and 2-
substituted pyridines have previously been shown to be potent anti-neoplastic agents in the Ehrlich ascites
carcinoma screen [1,2]. Cytotoxicity was demonstrated against L1210 and Tmolt leukemias, as well as
human solid tumor growth, e.g. HeLa, KB nasopharynx, skin, bronchogenic lung carcinomas, bone
osteosarcoma and glioma. A mode of action study with copper(II) complexes in L1210 leukemia cells
showed that DNA synthesis followed by RNA synthesis was inhibited. The major enzymatic sites of
inhibition by the agents include: IMP dehydrogenase, dihydrofolate reductase, DNA polymerase ,
ribonucleoside reductase, and nucleoside kinase [1,2]. More important was the observation that DNA
strand scission occurred after 24 hr. incubation with the agents. There did not appear to be any evidence
of cross linking ofthe DNA nor did the agents produce intercalation between nucleic bases ofDNA. The
copper complexes of the heterocyclic thiosemicarbazones, thioureas and 2-substituted pyridines were
shown to be L1210 DNA topoisomerase II inhibitors much like the agent fostriecin in that they were
competitive blockers of VP-|6’s induction ofDNA protein linked breaks [3-5]. The present investigation
involves an in-depth study of the nickel complexes regarding their mode of action in L1210 leukemia
cells.
Methods
All test compounds were previously synthesized and their chemical and physical characteristics
reported[6,7], i.e. Compound #1 [Ni(Appip)]2, compound #2 [Ni(pip)Br] and compound #3 [H2Appip]
[Fig 1]. All radioisotopes were purchased from New England Chemical Co. (St. Louis, MO).
Radioactivity was determined in Fisher Scintiverse scintillation fluid with correction for quenching.
Substrates and cofactors were obtained from Sigma Chemical Co.
Pharmacological methods
Compounds 1 and 2 (Table 1) were tested for cytotoic activity by homogenizing drugs in a 1 mM
solution in 0.05% Tween 80/I-I20. These solutions were sterilized by passing them through an acrodisc
(0.45 tt). The following cell lines were maintained by literature techniques[I,2]: murine L1210 lymphoid
leukemia, human Tmolt3 acute lymphoblastic T cell leukemia, colorectal adenocarcinoma SW480, lung
bronchogenic MB-9812, osteosarcoma TE418, KB epidermoid nasopharynx, I-IeLa-S suspended cervical
carcinoma, and glioma Eli 118 MG. Geran et al.’s protocol [8] was used to assess the cytotoxicity of the
compounds and standards in each cell line. Values for cytotoxicity were expressed as ED50 tg/ml, i.e.
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the concentration of the compound inhibiting 50% of cell growth. ED50 values were determined by the
trypan blue exclusion technique. A value of less than 4 tg/ml was required for significant activity of
growth inhibition. Standard agents, e.g. 5-fluorouracil [5-FU], 6-mercaptopurine [6-MP], cytidine
arabinoside [Ara-C], etoposide [VP-16], were also determined in the cytotoxic screens.
Figure Structures ofNickel Complexes
Compound 1 [Ni(Appip)]2
H
Compound 2 [Ni(Fopip)Br]
Compound 3 H2Appip
Solid tmnor cytotoxicity was determined by Liebovitz et al. ’s method [9] utilizing 0.2% crystal violet/20%
MeOH and read at 580 nm (Molecular Devices). In vivo anti-neoplastic activity in the Ehrlich ascites
carcinoma was conducted in CFI male mice [30 g]. Compounds were administered at 8 mg/kg, I.P. on
days 1-9. The animals were sacrificed on day 10, and the volume of tumor and astrocrit determined. 6-
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Mercaptopurine was used as an internal standard. Percent inhibition of tumor growth was determined
according to the literature 10].
Incorporation Studies
Compound 1 was selected for a mode of action study in L1210 leukemia cells based on its cytotoxic
action. Incorporation of labeled precursors into 3H-DNA, 3H-RNA and 3H-protein for 106 L1210 cells
was obtained 11]. The concentration response at 10, 25, 50 and 100 tM required for inhibition ofDNA,
RNA and protein synthesis was determined for 60 min incubations. The incorporation of 14C-glycine
(53.0 mCi/mmol) into purines was obtained by the method of Cadman et al. [12]. Incorporation of 14C-
formate (53.0 mCi/mmol) into pyrimidines was determined by the method ofChristopherson et al 13].
Enzyme Assays
Inhibition studies of various enzyme activities were performed by first preparing the appropriate L1210
cell homogenates or subcellular fractions, then adding the drug to be tested during the enzyme assay. For
the concentration response studies, inhibition of enzyme activity was determined at 10, 25, 50 and 100
tM ofcompound 1, after 60 min incubations. DNA polymerase ot activity was determined in cytoplasmic
extracts isolated by Eichler et al. ’s method[ 14]. Nuclear DNA polymerase 13 was determined by isolating
nuclei 15]. The polymerase assay for both alpha and beta was described by Sawada et al. 16] with 3H-
TTP. Messenger-, ribosomal- and transfer-RNA polymerase enzymes were isolated with different
concentrations of ammonium sulfate; individual RNA polymerase activities were determined using 3H-
UTP [17,18]. Ribonucleoside reductase activity was measured using laC-CDP with dithioerythritol [19].
The deoxyribonucleotides 14C-dCDP were separated from the ribonucleotides by TLC on PEI plates.
Thymidine, TMP and TDP kinase activities were determined using 3H-thymidine (58.3 mCi/mmol) in the
medium of Maley and Ochoa [20]. Carbamyl phosphate synthetase activity was determined with the
method ofKalman et al. [21]; citrulline was determined colorimetrically [22]. Aspartate transcarbamylase
activity was measured by the method of Kalman et a/.[21]; carbamyl aspartate was determined
colorimetrically [23]. Thymidylate synthetase activity was analyzed by Kampf et al. ’s method [24]. The
3H9O measured was proportional to the amount ofTMP formed from 3H-dUMP. Dihydrofolate reductase
activity was determined by the spectrophotometric method of Ho et a/.[25]. PRPP amidotransferase
activity was determined by Spassova et al. ’s method [26]; IMP dehydrogenase activity was analyzed with
8-14C-IMP (54 mCi/mmol) (Amersham, Arlington Heights, IL) atter separating XMP on PEI plates
(Fisher Scientific) by TLC [27]. Protein content was determined for the enzymatic assays by the Lowry
technique[28]. After deoxyribonucleoside triphosphates were extracted [29], d[NTP] pool levels were
determined by the method ofHunting and Henderson[30] with calfthymus DNA, E. coli DNA polymerase
I, non-limiting amounts of the three deoxyribonucleoside triphosphates not being assayed, and either 0.4
mCi of(3H-methyl)-dTTP or (5-3H)-dCTP.
DNA Studies
The effects of compound 1 on DNA strand scission was determined by the methods of Suzuki et al. [31 ],
Pera et a/.[32] and Woynarowski et aL[32]. L1210 lymphoid leukemia cells were incubated with 10 tCi
thymidine methyl-3H, 84.0 Ci/mmol for 24 hr at 37C. L1210 cells (107) were harvested and then
centrifuged at 600 g X 10 min in PBS. They were later washed and suspended in ml of PBS. Lysis
buffer (0.5 ml; 0.5 M NaOH, 0.02 M EDTA, 0.01% Triton X-100 and 2.5% sucrose) was layered onto a
5-20% alkaline-sucrose gradient (5 ml; 0.3 M NaOH, 0.7 KC1 and 0.01 M EDTA); this was followed by
0.2 ml of the cell preparation. After the gradient was incubated for 2.5 hr at room temperature, it was
centrifuged at 12,000 RPM at 20C for 60 min (Beckman rotor SW60). Fractions (0.2 ml) were collected
from the bottom of the gradient, neutralized with 0.2 ml of 0.3 N HC1, and measured for radioactivity.
Thermal calf thymus ct-DNA denaturation studies and ct-DNA viscosity studies were conducted aer
incubation of compound 1 at 100 tM at 37C for 24 hr [33]. L1210 DNA topoisomerase II was isolated
by the method ofLiu et al. [34] and the activity was determined by the method of Rowe et al. 35].
Statistics
The mean and standard deviation are designated by "X + SD." The probable level of significance (p)
between test and control samples was determined by the Student’s "t" test with the raw data.
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Results
The nickel complexes demonstrated mixed results in the Ehrlich ascites carcinoma screen compound 1
afforded 99.5% inhibition at mg/kg/day, I.P. Compounds 2 and 3 caused 28% and 67% reduction of
tumor growth at 8 mg/kg/day, I.P., respectively. Cytotoxicity was demonstrated by all three compounds
against the growth of murine or human leukemias, human HeLa uterine suspended carcinoma, colon
adenocarcinoma SW480, KB nasopharynx, lung MB 9812 bronchogenic carcinomas, but only compounds
1 and 2 were active against solid HeLa uterine carcinoma and rat osteosarcoma growth. The ED50 needs
to be < 4 gg/ml for significant activity. The compounds were not active against the growth ofhuman lung
A 549, ileum adenocarcinoma HCT-8, and skin epidermoid A431 cell growth [data not shown].
Table The Cytotoxicity ofthe Nickel Complexes ED50 tg/ml
Cpd #1
Cpd #2
Cpd #3
VP-16
6MP
Ara-C
5-FU
L1210 Tmolt3 HeLa S HeLa Colon KB UMR Lung
Lymphoid Leukemia Uterine Solid Adenocarci Naso- Osteo- MB-
Leukemia T Cell Carcinoma Uterine noma pharynx sarcoma 9812
SW480
1.32 3.59 2.97 1.82 2.14 3.62 3.67 4.02
1.81 1.02 2.76 3.50 1.13 1.82 2.46 0.77
2.98 3.56 1.37 7.34 2.72 2.78 6.35 2.21
1.83 7.87 3.05 3.34 3.32 3.57 3.50
2.43 1.62 2.12 5.61 3.61 11.04 9.13 4.29
2.42 2.67 2.13 4.74 342 2.84 0.86 6.16
1.41 1.41 2.47 4.11 3.09 1.25 3.52 5.64
The mode of action study with compound 1 in L1210 cells showed that DNA synthesis was reduced
greater than 65% at 25 txM and 99% at 100 txM whereas RNA and protein syntheses were inhibited 37%
and 34% respectively after 60 min at 100 tM of compound 1. DNA polymerase a activity was reduced
55% and m-RNA polymerase activity was reduced 33% at 100 tM but r- and t-RNA polymerase activities
were not affected by compound 1. Ribonucleoside reductase activity was only reduced 20% but
dihydrofolate reductase activity was inhibited 54% after 60 min at 100 lxM. De novo purine synthesis was
inhibited in a concentration dependent manner with 63%,,reduction at 100 tM. The activities of both
regulatory enzymes of the pathway were reduced PRPP amido transferase activity by 56% and IMP
dehydrogenase activity 54% by compound I. De novo pyrimidine synthesis was not significantly affected
by compound 1 nor were the early regulatory enzymes of the pathway affected. Thymidylate synthetase
activity was reduced 44% and thymidine-monophosphate kinase activity was reduced 49% at 100 tM.
TDP kinase activity was elevated 185% by compound 1. The d[GTP] pool level was reduced 13% and
d[CTP] and d[TTP] pool levels were elevated 68-78% ater 60 min incubation with compound 1. L1210
DNA strand scission did occur with compound 1 after incubation for 24 hr. at 100 laM [Fig 2]. ct-DNA
studies demonstrated that DNA viscosity was reduced from 323 see for the control to 283 see. for
compound 1 indicating smaller fragments of DNA. The DNA thermal denaturation Tm value for the
control was 87.5C and was 92C for compound 1. L1210 DNA topoisomerase activity was not affected by
compound I at 100 tM.
Discussion
The nickel(II) complexes of thiosemicarbazones proved to be potent anti-neoplastic and cytotoxic agents.
The complexes did demonstrate some specifi.city for select tumor growth inhibition. The two nickel
compounds tested previously demonstrated significant activity in the ileum adenocarcinoma, and skin
A431 screens and were more potent in the KB nasopharynx and osteosarcoma screens[ ], but the two new
nickel complexes I and 2 were more potent in the L1210 screen. The mode of action in L1210 leukemia
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Talle 2 The Effects ofthe Nickel,Complex on Ll210 Nucleic Acid Metablism
Percent OfControl
DNA synthesis
protein ,synthesis
DNA polymerase a
m-RNA P01ymerase
r-RNA polymerase...
t-RNA polymerase
bonucleoside reductase
Purine de novo synthesis
PPRPamido-transferase
iMP dehydrogenase
Pyrimidine de n0vo synthesis
Cambamyl PhosPhate synthetase,
Aspartate transcarbamylase,
Th,ymidine s,ynthetase
Thymidine kinase
TMP kinase
TDP kinase
Dihydrofolate reductase
d(ATP)
d(GTP)
:d(CTP)
,d(TTP)
Control Compound
25 uM 50 uM 100 uM
100+5 33-4" 28+4* 1+1"
1004-6 133+7’"77+5’63+5
1004-4 116+9 836 !66-_4
100+/-5 63+5’ 53+_4 45+_4
1004-6 69+5 69+4 67+4
1004-5 126+7 111+8 101+6
100+8 "119+6 i4+5 99/__4
1004-6 91/6 86/5 80+5
100-:7 95+5 50+5 37+4
1004-8 153+7 ’89+5 44+4
100+/-5 70+6 68+5 46+3
1004-7 99+6 97+5 i01+5
1007 101+6 115+6 127+7
1004-6 !96/5 93+5 90-5
1004-6 63+5 61+4 56+4
100-6 158+8 137+6 85+5
00-5 124+6 94+5 51+4
100+/-5 i42+7 250+6"285+6
1004-4 82+6 68+5 46+4
1004-6 87+6
1004-6 100+5
1004-7 168+6
100+5 178+7
cell for the nickel complex was Similar to that of the copper(Ii) c0mplexe"of hiosemicarbazones [2].
DNA synthesis was the major target of the nickel complexes with marginal effects on RNA and protein
synthesis after 60 rain. Inhibition ofDNA polymerase a activity by the compound was one of the reasons
DNA synthesis was suppressed. This effect on this enzyme was similar to that observation with the
copper(II) complexes as were the mixed effects on the RNA polymerase activities. The copper(II)
complexes did have a higher magnitude of inhibition for ribonucleoside reductase activity[I,2] than the
nickel compound; however, inhibition ofthis enzyme would be additive with the overall reduction ofDNA
synthesis since there would be a reduction in the deoxyribonucleosides and deoxyribonucleotides in the
nucleus for their incorporation into DNA.
A major site of inhibition of the nickel complex was in the purine pathway of L1210 cells. Both
regulatory enzymes were markedly reduced in activity, similar to the effects afforded by 6-MP. This
would lead to reduced deoxyribopurines as well as inhibition of DNA synthesis and cell death. There
were not apparent blocks by the agent in the pyrimidine pathway, although some inhibition ofthymidylate
synthetase activity occurred. The elevation of TDP-kinase activity by the nickel complex may help
explain the observed elevation ofdeoxyribopyrimidine pools. On the other hand, the d[NTP] pools would
be elevated in the cell ifDNA polymerase c was inhibited in that the deoxytriphosphate nucleotides were
not incorporated into the new strand ofDNA. The nickel complex did cause fragmentation ofDNA but
did not cause alkylation ofbases ofDNA or intercalation between base pairs. The nickel complex did not
inhibit L1210 DNA topoisomerase II activity. The copper complexes of thiosemicarbazones were potent
inhibitors ofL1210 DNA topoisomerase II activity and were able to cause DNA protein linked breaks[2].
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Figure 2 The L1210 DNA Strand Scission
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